XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics. Its proprietary product candidates are X358, X213, X129, and Gevokizumab. The business operations of the company are functioned through the United States, Europe, and the Asia Pacific. XOMA's primary source of revenue is from license and collaboration arrangements, contract services, and royalties and the majority of the revenue is generated from the United States.
Emeryville, CA, 94608